Taste Masking
Developing novel pharmaceutical technology that provides for outstanding taste masking for a broad range of pharmaceuticals including major drug categories such as NSAIDS and statins.
News
31 August 2011
Exclusive Option to License of Drug Delivery Technology from
The London School of Pharmacy
Oxford Pharmascience, the speciality pharmaceutical company that uses advanced drug delivery technologies to reposition medicines, is pleased to announce that it has signed a worldwide exclusive option for up to 18 months to license and research an advanced colonic drug delivery technology from The School of Pharmacy, University of London, with a specific intention to develop and commercialise a novel application.
The platform technology, which has been developed by Abdul Basit and his research group at the world renowned London School of Pharmacy, provides for superior controlled delivery of drugs to the colon. The targeting of drugs to the colon can be utilised as a means to achieving localised therapy for disease states such us irritable bowel syndrome, constipation, diarrhoea, infection and carcinoma, but also as a portal for the entry of drugs into the systemic circulation potentially improving the clinical profile of certain drugs. An international patent application for the technology was filed in 2007, with a priority claim to an earlier British case filed in 2006 which is now entering the national and regional phase.
Marcelo Bravo, Chief Technology Officer of Oxford Pharmascience commented,
"Accessing cutting edge technology from a strong academic partner such as the London School of Pharmacy gives Oxford Pharmascience significant capability to innovate and extend the lifecycle of off-patent and soon to be off-patent drugs.
The superior colon targeting and drug release profile achieved by London School of Pharmacy's drug delivery technology will enable us to develop a next generation application for a major drug category across markets worldwide."
For further information:
| Oxford Pharmascience Group Plc | |
| Nigel Theobald, Chief Executive | +44 1865 854874 |
| ZAI Corporate Finance (Nominated Adviser) | |
| John Depasquale | +44 20 7060 2220 |
| Sarang Shah | +44 20 7060 2220 |
| Hybridan LLP (Broker) | |
| Claire Noyce | +44 20 7947 4350 |
About Oxford Pharmascience Group Plc
- Oxford Pharmascience are specialists in the repositioning of medicines via reformulation using advanced pharmaceutic technologies adding value to generic and soon to be off patent Active Pharmaceutical Ingredients (API's),
- Technology portfolio includes superior chewable tablets, liquid suspensions, and solid state suspensions (soft chews) as well as modified drug delivery technologies to achieve either taste masking or targeted release effects.
- The Company uses its technologies to develop Drug Master Files (DMF's) and full CTD dossiers (drug registration dossiers) for a range of medicines initially with focus on NSAIDs, statins and calcium.
- Oxford Pharmascience works closely with leading academic institutions to further advance its intellectual property portfolio to apply to generic and soon to be generic drugs.
About The School of Pharmacy, University of London
- The School of Pharmacy is dedicated to teaching and research in pharmacy and pharmaceutical sciences; with world-class teaching and a top research rating.
- Research focuses on advancing and understanding medicines and health care, and in creating new medicines. It is organised into four divisions which include Drug Discovery, Formulation Sciences, Neurosciences and Medicines Use and Health.
- In the 2008 Research Assessment Exercise for British universities 90 per cent of the research activity at The School of Pharmacy was deemed internationally significant and 25 per cent world-leading.